Seres Therapeutics, Inc. Income (Loss) from Continuing Operations, Per Diluted Share
Seres Therapeutics, Inc. (MCRB) reported Income (Loss) from Continuing Operations, Per Diluted Share of $0.47 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare · last filed 2026-08-05
- Seres Therapeutics, Inc. income (loss) from continuing operations, per diluted share for the quarter ending 2026-06-30 was $0.47.
- Seres Therapeutics, Inc. income (loss) from continuing operations, per diluted share for the quarter ending 2026-03-31 was -$2.08, a 155.47% decline year-over-year.
- Seres Therapeutics, Inc. income (loss) from continuing operations, per diluted share for the quarter ending 2025-09-30 was $0.94.
- Seres Therapeutics, Inc. income (loss) from continuing operations, per diluted share for the quarter ending 2025-06-30 was -$2.27.
- Seres Therapeutics, Inc. income (loss) from continuing operations, per diluted share for fiscal 2025 was $0.64.
- Seres Therapeutics, Inc. income (loss) from continuing operations, per diluted share for fiscal 2024 was -$16.20.
- Seres Therapeutics, Inc. income (loss) from continuing operations, per diluted share for fiscal 2023 was -$29.71.
- Seres Therapeutics, Inc. income (loss) from continuing operations, per diluted share for fiscal 2022 was -$1.70.
| Period end | Income (Loss) from Continuing Operations, Per Diluted Share 3 month | Income (Loss) from Continuing Operations, Per Diluted Share 3 month as first filed | Income (Loss) from Continuing Operations, Per Diluted Share 6 month | Income (Loss) from Continuing Operations, Per Diluted Share 9 month | Income (Loss) from Continuing Operations, Per Diluted Share 9 month as first filed | Income (Loss) from Continuing Operations, Per Diluted Share 12 month | Income (Loss) from Continuing Operations, Per Diluted Share 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.47 10-Q · filed 2026-08-05 | -$1.59 10-Q · filed 2026-08-05 | |||||
| 2026-03-31 | -$2.08 10-Q · filed 2026-05-05 | ||||||
| 2025-12-31 | $0.64 10-K · filed 2026-03-12 | ||||||
| 2025-09-30 | $0.94 10-Q · filed 2025-11-05 | $2.40 10-Q · filed 2025-11-05 | |||||
| 2025-06-30 | -$2.27 10-Q · filed 2026-08-05 | $1.47 10-Q · filed 2026-08-05 | |||||
| 2025-03-31 | $3.75 10-Q · filed 2026-05-05 | ||||||
| 2024-12-31 | -$16.20 10-K · filed 2026-03-12 | -$0.81 10-K · filed 2025-03-13 | |||||
| 2024-09-30 | -$6.69 10-Q · filed 2025-11-05 | -$0.33 10-Q · filed 2024-11-13 | -$14.68 10-Q · filed 2025-11-05 | -$0.73 10-Q · filed 2024-11-13 | |||
| 2024-06-30 | -$3.46 10-Q · filed 2025-08-06 | -$7.94 10-Q · filed 2025-08-06 | |||||
| 2024-03-31 | -$4.50 10-Q · filed 2025-05-07 | ||||||
| 2023-12-31 | -$29.71 10-K · filed 2026-03-12 | -$1.49 10-K · filed 2025-03-13 | |||||
| 2023-09-30 | -$0.32 10-Q · filed 2024-11-13 | -$1.22 10-Q · filed 2024-11-13 | |||||
| 2022-12-31 | -$1.70 10-K · filed 2025-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |